Will GlaxoSmithKline plc’s Global Ambitions Make It A Buy?

Could GlaxoSmithKline plc (LON: GSK)’s future lie in emerging markets?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The story of the twentieth century was, in essence, the story of one country: America.

This one nation played a key role in the First World War, the Second World War, the post-war boom, the Cold War, and modern consumerism.

During this time, it grew and grew to become, by some distance, the wealthiest and most powerful country on Earth.

The most powerful nation on Earth has no healthcare system

The story of the twenty-first century will, in essence, also be about one country: China. Many are talking about the China boom. But don’t be suckered into thinking the current trouble is a car crash like the Credit Crunch was; the Chinese juggernaut is merely waiting at the traffic lights. Believe me, this country’s time has now come.

Having said this, the Middle Kingdom has a huge number of problems. Mass industrialisation has meant that pollution levels are some of the highest in the world. Despite a booming economy, there are still tens, perhaps hundreds, of millions of unemployed and dispossessed.

And this new wave of wealth has meant rocketing levels of heart disease, diabetes and cancer. Yet there is no national health service as there is in, say, Britain or France. And there is precious little healthcare insurance or provision in pension plans. In short, you’re okay if you are healthy, but woe betide you if you fall seriously ill.

After the horrors of the Second World War, the most important thing Britain’s post-war government did was launch the National Health Service. Thousands of doctors and nurses were recruited and what was a disparate collection of surgeries and hospitals was drawn together into a unique organisation.

China is on the brink of doing something similar. It will take billions of yuan, and a massive training and recruitment programme, but this will naturally follow from the fact of this nation’s new-found riches. After all, what do people in a nouveau riche country want? An empire? A massive nuclear arsenal? No to both of these — they want a good healthcare system.

This means opportunity

And this means opportunity. One of Britain’s great strengths is its pharmaceutical companies. In GlaxoSmithKline (LSE: GSK) and AstraZeneca, this country has two of the leading, and most coveted, drugs firms in the world.

While AstraZeneca’s focus is on big-money anti-cancer treatments, GSK is aiming to expand in emerging markets, where its array of consumer healthcare products and over-the-counter medicines should sell in astonishing numbers. While AZ has gone for the high-margin, research-intensive, developed world approach, GSK is realising there are fewer opportunities in blockbuster drugs and more in cheap but effective treatment for the masses. And, in emerging markets, this mass market numbers in the billions.

That’s why I expect Glaxo to edge down its scientific research and concentrate more of its resources on cost-effective treatments for emerging markets, where it will sell brands such as Zovirax, Aquafresh and Panadol. In doing so, it will follow the path of consumer goods giants such as Unilever and Reckitt Benckiser.

It’s a strategy that none of the other pharmaceutical companies has yet attempted. I will watch Glaxo’s progress with interest. You see, everyone knows that the future of healthcare companies is in emerging markets. But I’m not sure we have yet worked out what that future is.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline, and has both recommended and owns shares in Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »